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Abstract
Objective—To examine the role of estradiol fluctuation in triggering depressive symptoms in the 
menopause transition and assess the role of recent very stressful life events (VSLEs) as a 
moderating factor in this relationship.
Methods—52 euthymic women in the menopause transition or early postmenopause (age 45–60) 
who were assigned to the placebo arm of a randomized controlled trial of hormone therapy 
provided the data for this report. At enrollment, women’s experience of recent VSLEs, depressive 
symptoms, serum estradiol and progesterone were assessed. At months 1, 8 and 14, depressive 
symptoms and hormones were re-assessed and participants underwent a stressor battery involving 
a speech and a mental arithmetic task. Participants rated their feelings of anxiety, fear, anger and 
rejection. The standard deviation of estradiol provided an index of hormone variability over the 
entire 14 months.
Results—Greater estradiol variability across the 14 months predicted greater depressive 
symptoms at month 14, though only in women reporting a higher number of VSLEs at baseline 
(39% of women reported ≤1 recent event). Greater estradiol variability also predicted greater 
feelings of rejection to the laboratory stressor at months 8 and 14. Furthermore, among women 
reporting higher VSLEs at baseline, feelings of rejection in response to the laboratory stressor at 
month 8 predicted depressive symptoms at month 14.
Conclusion—These data suggest estradiol variability may enhance emotional sensitivity to 
psychosocial stress, particularly sensitivity to social rejection. Combined with VSLEs proximate 
to the menopause transition, this increased sensitivity may contribute to the development of 
depressed mood.
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Women’s lifetime prevalence of major depressive disorder (MDD) is double that of men’s1. 
Depressive episodes tied to reproductive events, including perinatal depression, 
premenstrual dysphoric disorder (PMDD), and depression with onset in the menopause 
transition (i.e. perimenopausal depression) may contribute in a substantial way to the gender 
disparity that exists in rates of MDD. Studies in women with PMDD and those with a 
history of postpartum depression that pharmacologically manipulate the hypothalamic-
pituitary-gonadal axis suggest that sensitivity to reproductive hormonal change, and not 
absolute levels of hormones, is pathophysiologically relevant to these disorders2, 3. The 
menopause transition and early postmenopausal period provides an ideal model in which to 
examine the influence of hormonal flux on mood destabilization and the development of 
depression in women4 for the following reasons: 1) the day-to-day variability in 
reproductive hormones can be significant during this period5 and 2) the menopause 
transition and early postmenopausal period is a time of particularly increased vulnerability 
to depression for women, with rates of MDD6 and clinical elevations in depressive 
symptoms7–9 roughly doubling to tripling compared to pre- and late postmenopausal rates.
Extreme variability in estradiol concentrations is particularly characteristic of the 
menopause transition, whereas progesterone fluctuation progressively declines over the 
menopause transition as women experience an increasing number of anovulatory cycles. 
Consequently, the role of estradiol fluctuation in the etiology of perimenopausal depression 
has been of particular interest. To our knowledge, five studies to date have evaluated the 
hormone variability hypothesis of perimenopausal depression by examining naturally 
occurring fluctuations in ovarian hormones in relation to depressive symptoms among 
perimenopausal women, with three of these studies6, 9, 10 obtaining null findings and two 
studies observing an association between hormonal fluctuation and depressive 
symptoms11, 12. The two positive studies differed from the negative studies in ensuring that 
they included exclusively women with depression onset in the menopause transition rather 
than women whose symptoms began prior to, and continued into, the menopause transition. 
Second, the negative studies assessed hormone levels at most once annually, while the 
positive studies used more frequent hormonal assessments. Specifically, in one11, ten 
assessment periods occurred over 8 years, each consisting of two blood draws taken one 
month apart. Estradiol variability at each assessment was calculated as the standard 
deviation across the two levels obtained during each assessment period and was found to 
predict both increased depressive symptoms (Center for Epidemiologic Studies Depression 
Scale - CES-D > 16) (OR = 1.30) and DSM-IV diagnosed depressive disorders (OR = 2.22). 
In the other positive study12, follicle stimulating hormone (FSH) was measured once weekly 
for six weeks and hormonal change was calculated as the difference between week six and 
baseline FSH levels. This study found that those women who experienced a 50% drop in 
FSH over six weeks, indicative of a return to premenopausal ovarian function, experienced a 
significant decline in depressive symptoms (five-point decline on the CES-D). Taken 
together, these results suggest that studies employing more frequent assessment of ovarian 
hormone variability and studying exclusively depression with onset in the menopause 
transition may advance our understanding of the role of hormonal variability in the etiology 
of perimenopausal depression.
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A substantial proportion of women, 26–33%,6–9, 13 will develop clinically significant 
depressive symptoms within the context of perimenopausal hormonal flux. However, 
because the majority will not develop depression symptomatology, identification of potential 
moderators of the relationship between hormonal flux and the emergence of affective 
symptomatology may inform preventative intervention efforts. In a recent conceptual 
review4, we have proposed a model of perimenopausal depression development whereby 
estradiol fluctuation increases sensitivity to stress such that in the context of stressful life 
events proximate to the menopause transition, clinical elevations in depressive symptoms 
may ensue. Such a model would be consistent with the observation that while hormonal 
influences are believed to play a role in perimenopausal depression development, 
psychosocial stress, including unemployment8, financial strain7, lack of social support7 and 
recent stressful life events6, 7 also predict increased risk for both depressive symptoms and 
syndromal MDD during the menopause transition. Notably, in a large scale, prospective 
epidemiologic study of women’s health across the nation (the SWAN study), very stressful 
life events were found to be the strongest predictor of elevated depressive symptoms in the 
menopause transition7.
The goals of the current preliminary report were therefore threefold: 1) To examine the 
relationship between estradiol variability and depressive symptomatology with onset in the 
menopause transition using more frequent hormone assessments than in previous studies; 2) 
To explore stressful life events proximate to the menopause transition as a candidate 
moderator of this relationship; and 3) To investigate increased sensitivity to psychosocial 
stress as a mechanism underlying any relationship observed between estradiol variability 
and perimenopausal depressive symptoms.
Methods
Participants
The women included in this report were recruited from the community to participate in the 
Perimenopausal Estrogen Replacement Therapy (PERT) Study, a 12-month placebo-
controlled randomized trial evaluating the mood and cardiovascular benefits of transdermal 
estradiol in perimenopausal women. Women were recruited who were aged 45–60 years, 
medically healthy and perimenopausal or early postmenopausal according to the Stages of 
Reproductive Aging Workshop (STRAW+10) criteria (early perimenopause, defined as 
menstrual cycle length 7+ days longer than usual; late perimenopause, defined as ≥ 2 
skipped cycles and an interval of amenorrhea ≥ 60 days but within one year of the last 
menstrual period and early postmenopause defined as an interval of amenorrhea between 
one and two years). Women who had partial hysterectomies (at least one ovary retained) for 
whom menstrual bleeding patterns could not be assessed were included in the study if: 1) 
they were experiencing vasomotor symptoms and their baseline estradiol levels were above 
postmenopausal concentrations (> 40 pg/ml) (n = 8) or, 2) they were not experiencing 
vasomotor symptoms but had baseline estradiol > 40 pg/ml and baseline FSH levels > 14 
pg/ml (n=0) (a cutoff of two standard deviations above the mean level obtained from a 
sample of premenopausal women, consistent with STRAW guidelines14.
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Exclusion criteria included the following: current psychiatric diagnosis of MDD or any other 
current psychiatric diagnosis with severity greater than mild, a history of severe substance 
use within the past 10 years, a history of suicide attempts, use of psychotropic medication, 
hormonal preparations, or herbal compounds indicated for menopausal symptoms (e.g. 
Black Cohosh) or mood (e.g., St. John’s Wort), use of statins or antihypertensive agents 
other than diuretics, regular over-the-counter medication use (e.g., non-steroidal anti-
inflammatory agents), or blood pressure >160/90 mmHg. Multiple exclusion criteria aimed 
at minimizing risk related to hormone therapy also applied and included the following: 
endometrial hyperplasia, abnormal uterine anatomy, history of thrombophlebitis or 
thromboembolic disorders, history of estrogen-dependent neoplasias, body mass index > 35. 
To be eligible for the study, women also must have had a normal mammogram within one 
year of study enrollment. The study protocol was approved by the institution’s Institutional 
Review Board. All participants provided informed, written consent prior to participating and 
received up to $1525 in compensation for participating in full compliance.
The data reported herein are derived from 52 women who were randomized to the placebo 
arm of the trial. These women wore a placebo patch in place of a transdermal estradiol patch 
(0.1 mg) and took placebo pills every other month in place of micronized progesterone pills 
(200 mg/day). It should be noted that the analyses for this report were conducted by the first 
author who was unblinded to treatment assignment but had no interaction with the research 
participants and no access to identifiable data. The participants remained blinded throughout 
the protocol. While this study was not specifically designed to examine the association of 
hormone variability and the onset of depressive symptoms in the menopause transition, the 
multiple assessments of ovarian hormones, stress responses to a standardized psychosocial 
laboratory stressor and depressive symptoms nonetheless makes it uniquely suited to do so. 
Although the entire trial will be completed in March 2016, early dissemination of the present 
results is intended to serve a heuristic purpose in informing both the design and analyses of 
other studies investigating the etiology and treatment of perimenopausal depression, which 
is currently gaining much attention15–18.
Study Overview
Figure 1 depicts the overall study design. Participants first underwent an enrollment visit 
during which their study eligibility was determined and informed written consent was 
obtained. At this time, participants completed questionnaires pertaining to their demographic 
characteristics, medical history and current menopausal symptoms; participants’ experience 
of stressful life events in the past six months was also assessed. One month following the 
enrollment session, those women who were determined to be eligible completed the first 
laboratory stress testing session, which included the Trier Social Stress Test (TSST). They 
were subsequently randomized to the active estradiol patch and micronized progesterone 
pills or the placebo patch and pills, though only women randomized to placebo are included 
in this manuscript. Six and twelve months later (months 8 and 14), participants repeated the 
stress testing protocol. This schedule was determined by the protocol of the RCT from 
which this study was derived; consequently, this was a convenience sampling protocol. At 
all four time points, serum estradiol and progesterone and depressive symptoms were 
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measured. At baseline, estradiol and progesterone were measured between 8:00 and 10:00 
a.m. while at months 1, 8 and 14, they were measured between 1:00 and 2:00 p.m.
The Trier Social Stress Test (TSST)
All laboratory sessions began at 1:00 p.m. and involved a 40-minute quiet rest period, the 
last 10 minutes of which served as the pre-stress baseline, the administration of the TSST, 
and a 60-minute recovery period.
The TSST, which has been shown to induce a reliable stress response19, involved four 
components: 1) Pre-task instructions (1 minute) during which participants were introduced 
to the committee who later listened to their job talk and were given instructions for the 
mental arithmetic task; 2) Speech preparation period (5 minutes) during which participants 
prepared their job talk while the selection committee stood in the room; 3) Job speech (5 
minutes) - immediately following the preparation period, the selection committee asked the 
participant to deliver his/her job talk. The exact topic of the job talk was different at each of 
the three laboratory sessions to minimize habituation. If the participant ended their talk 
before 5 minutes, the selection committee questioned the participant in a systematic fashion 
to ensure the participant would speak the entire 5 minutes. 4) Serial subtraction task, which 
involved subtracting a 1-digit number from a 4-digit number as fast and as accurately as 
possible for 5 minutes. The numbers differed at each test session. For each mistake, the 
participant was instructed by a member of the selection committee to restart from the 
beginning. Participants were video-recorded throughout their performance.
Following the recovery period, participants were asked to rate on a scale from 0 to 10 the 
extent to which the job speech and the arithmetic task caused them anxiety, fear, anger/ 
hostility and feelings of rejection. Using a similar scale, participants also rated how difficult 
the tasks were and how much effort they exerted in completing the tasks. However, because 
we have found the speech to be a more potent stressor inducing greater negative affective 
responses, we have only analyzed emotional responses to the speech task in the current 
manuscript.
Estradiol and Progesterone Assays
Serum estradiol and progesterone were determined using radioimmunoassay (RIA) 
techniques (MP Biomedicals). Intra-assay coefficients of variation were 5.5% for estradiol 
and 5.1% for progesterone, while inter-assay coefficients were 7.6% for estradiol and 8.5% 
for progesterone.
Measures
Depressive symptoms were assessed using the Center for Epidemiologic Studies- 
Depression Scale (CES-D), a 20-item self-report form that asks about the frequency of 
depressive symptoms during the previous week on a 4-point scale of 0 (rarely) to 3 (most or 
all of the time)20. A score of 16 or above is commonly used as a cutoff for identifying 
potential clinical depression21 and is predictive of major depression22. The CES-D has been 
frequently used in perimenopausal samples6, 9–12.
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Recent total and very stressful life events were measured using a modified version of the 
Life Events Survey (LES)23, 24 that assesses the presence of stressful events during the 6 
months before the baseline assessment. The list had been modified to include only those 
events that are considered moderate to severely stressful based on previous studies with 
interviewer-based objectively rated stresses25–27. This interviewer-based objective rating has 
been shown to be consistently related to immune decline and HIV disease progression25–27. 
More recently, the modified LES questionnaire has been shown to predict non-adherence27 
and worse physical functioning and pain28 in HIV infected men and women.
Using the LES, the distinction can be made between total stressful life events and very 
stressful life events, which includes only divorce or separation from a partner, serious illness 
or death of a close family member or close friend, a major worsening in one’s financial 
status or major chronic financial problems (e.g. months behind in bills, foreclosure on a 
mortgage), being physically attacked or having one’s life threatened, being sexually abused 
or assaulted, being arrested for a serious crime or having a mate or close relative arrested for 
a serious crime. The selection of these six specific events is based on the research of 
Leserman and colleagues finding that these events are experienced as very stressful in a 
particularly high proportion of participants and are uniquely predictive of negative health 
outcomes in chronically ill populations26, 29. Stressful life events not considered “very 
stressful” included such things as getting married or engaged, working long hours or 
changing residences more than once. In the current study, we examined both the number of 
total stressful life events and the number of very stressful life events an individual 
experienced in the last 6 months in relation to depressive symptoms.
Vasomotor symptoms were measured using the Greene Climacteric Scale (GCS)30, a self-
report form that asks the participant to rate the extent to which they currently suffer from 21 
menopausal symptoms on a 4-point scale from ‘not at all’ to ‘extremely’ The Vasomotor 
Subscale of the GCS consists of two items: “hot flashes” and “sweating at night”. Construct 
validity of this scale has been established in multiple studies31–33.
Statistical Analyses
As recommended by Warner (2012)34, sensitivity analyses were used to identify extreme 
outliers prior to data analysis, defined as values 3 or more interquartile ranges below the first 
quartile or above the third quartile (SAS Institute Inc., 2011). This resulted in the removal of 
two extreme estradiol variability scores. Although the analyses presented are those with the 
outliers removed, analyses with the outliers retained yielded an identical pattern of results.
The standard deviation in estradiol and progesterone across all four measurements was used 
as respective indicators of estradiol and progesterone variability and used to predict 
outcomes at month 14. In three cases in which only the baseline hormone levels were 
missing, the standard deviation in estradiol and progesterone was calculated across the three 
existing levels (months 1, 8 and 14) to predict outcomes at month 14. For analyses 
predicting outcomes assessed at month 8, the standard deviation in estradiol and 
progesterone across only the first three assessments was used. As such, the three participants 
with missing baseline hormone levels were excluded from this analysis.
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Separate regression models were used to examine the main effects of estradiol variability 
and the number of baseline total and very stressful life events on CES-D score at months 8 
and 14. All analyses included baseline CES-D score as a covariate. This approach was 
chosen over a repeated measures analysis to examine the effect of estradiol variability on 
CES-D score at months 0, 1, 8 and 14 because it was reasoned that CES-D score at months 8 
and 14 should have two different predictors: estradiol variability measured until month 8 and 
estradiol variability until month 14, respectively. In a repeated measures analysis, the 
independent variable (estradiol variability measured across the 14 months) would partially 
be measured six months after the dependent variable (CES-D score at month 8), which 
would be inappropriate.
To examine total stressful life events as a potential moderator in the relationship between 
estradiol variability and depressive symptoms, the interaction between baseline total 
stressful life events and estradiol variability was examined in relation to CES-D score at 
months 8 and 14. Baseline CES-D score was included as a covariate. As such, the regression 
model included the following variables: total stressful life events, estradiol variability, total 
stressful life events X estradiol variability and baseline CES-D score. A similar regression 
model was conducted replacing total stressful life events with very stressful life events.
With the goal of exploring the role of increased stress sensitivity in linking estradiol 
variability and depressive symptoms, the main effect of estradiol variability as well as the 
interaction between estradiol variability and baseline total stressful life events were 
examined in relation to emotional responses to the TSST at months 8 and 14. Similar 
analyses were conducted using very stressful life events in place of total stressful life events. 
For all of these analyses, ratings of TSST difficulty and effort were included as covariates to 
account for any menopause transition-related declines in verbal memory35, 36.
In light of the prominent “domino hypothesis” of perimenopausal depression37, 38, which 
posits that vasomotor symptoms are responsible for triggering depressive symptoms through 
increased sleep disturbance, additional regression analyses examined the relationship 
between vasomotor symptoms and estradiol variability as well as the relationship between 
vasomotor symptoms and CES-D score. In addition, all regression models including 
estradiol variability as a predictor were rerun with the following potential confounders: age, 
race, body mass index (BMI), progesterone variability and estradiol levels.
All analyses were conducted using SAS v. 9.4.
Results
Participant Characteristics
As reflected in Table 1, the participants were of above-average socioeconomic status and 
reflected the racial demographics of our region (73% Caucasian, 23% African American, 
and 4% other). Twenty women (38.5%) endorsed at least one very stressful life event. These 
included: divorce (5 cases), death of a close friend or family member (5 cases), serious 
illness of a family member (4 cases), serious financial difficulty (7 cases) and one’s own 
serious illness or accidental injury (3 cases). Although a similar proportion of women 
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(30.8%) had a history of major depressive disorder, the overlap between very stressful life 
events and past depression was small, with only five past-depressed women endorsing at 
least one very stressful life event.
Depression scores were low at baseline; no participant scored >16 on the CES-D at baseline 
but roughly 8% did so at month 14. Based on STRAW +10 criteria, most women were in the 
late menopause transition (STRAW −1) at baseline and the majority remained in the 
menopause transition by the end of the study. Although 9% of women were postmenopausal 
at baseline according to STRAW+10 criteria, only one participant had a baseline estradiol 
level < 40 pg/ml. Repeated measures analyses revealed that post-TSST emotional ratings 
and ratings of difficulty and effort remained similar across the three administrations of the 
TSST (ps = .06–.78).
Estradiol Variability and Stressful Life Events Predicting Depressive Symptoms
Estradiol variability—When adjusting for baseline CES-D score, estradiol variability was 
not associated with CES-D score at either month 8 or 14 (ps >.10).
Total stressful life events—Adjusting for baseline CES-D score, the number of baseline 
stressful life events positively predicted CES-D score at month 8 (Mean difference = 1.9, p 
< .01) but not at month 14 (Mean difference = 1.4, p = .13).
Very stressful life events—Adjusting for baseline CES-D score, the number of baseline 
very stressful life events positively predicted CES-D score at month 8 (Mean difference = 
2.2, p = .05), and this relationship became stronger by month 14 (Mean difference = 4.1, p 
= .01).
Estradiol variability by total stressful life events interaction—Adjusting for 
baseline CES-D score, estradiol variability did not interact with stressful life events at either 
month 8 (Mean difference = 0.03, p = .42) or month 14 (Mean difference = 0.03, p = .21)
Estradiol variability by very stressful life events interaction—Adjusting for 
baseline CES-D score, there was a significant interaction between estradiol variability and 
the number of very stressful life events such that estradiol variability was associated with 
higher month 14 CES-D scores, but only in those women reporting a greater number of very 
stressful life events at baseline (Mean difference = 0.1, p = .03). Although estradiol 
variability and very stressful life events were analyzed as continuous variables, they have 
been split at the median for illustration purposes in Figure 2, which displays mean CES-D 
score as a function of high versus low estradiol variability and very stressful life events. An 
interaction between estradiol variability and very stressful life events was not observed at 
month 8 (p = .42). It should be noted that this finding was the same when a repeated 
measures analysis was used to assess the interactive effect of estradiol variability and very 
stressful life events on CES-D score at months 0, 1, 8 and 14: a significant estradiol 
variability by life stress by time interaction on CES-D score was found such that the 
interaction between estradiol variability and life stress was only significant at month 14.
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Estradiol Variability and Stressful Life Events Predicting Emotional Responses to the 
TSST
Estradiol variability—At month 8, higher estradiol variability was associated with greater 
anger/ hostility (Mean difference = 0.02, p < .01) and feelings of rejection (Mean difference 
= 0.05, p < .01) but not anxiety (p = .23) or fear (p = .08) in response to the TSST (Figure 3). 
This effect continued at month 14 for feelings of rejection (Mean difference = 0.02, p < .01) 
but not anger/ hostility (p = .51).
Total stressful life events—Adjusting for perceived difficulty and effort, the number of 
stressful life events reported at baseline predicted less anxiety (Mean difference = −0.41, p 
= .01) at month 8 but not at month 14 (p = .76) and did not predict the other emotional 
responses to the TSST at either time points (ps = .42–.93).
Very stressful life events—Adjusting for perceived difficulty and effort, the number of 
very stressful life events reported at baseline did not predict any emotional responses to the 
TSST at either month 8 or 14 (ps > .20).
Estradiol variability by very stressful life events interaction—There was no 
significant interaction between estradiol variability and very stressful life events in 
predicting emotional responses to the TSST at either month 8 or 14 (ps > .10).
Emotional Responses to the TSST at Month 8 Predicting Month 14 Depressive Symptoms
To further investigate the role of increased anger and rejection to the TSST as processes 
involved in estradiol variability’s negative mood effects among women experiencing very 
stressful life events, we investigated the ability of these emotional responses to the TSST at 
month 8, as well as the interaction between these emotional responses and baseline very 
stressful life events, to predict CES-D score at month 14. TSST-induced feelings of rejection 
at month 8 and the number of very stressful life events at baseline were found to interact in 
predicting month 14 CES-D score such that feelings of rejection at month 8 predicted 
depressive symptoms at month 14 only within the context of elevated very stressful life 
events (Mean difference = 1.1, p = .02). This was not the case for anger (p = .20). Although 
feelings of rejection and very stressful life events were examined as continuous variables, 
they have been split at the median for illustration purposes in Figure 4, which displays mean 
CES-D score as a function of high versus low feelings of rejection at month 8 and very 
stressful life events. Neither post-TSST anger (p = .10) nor rejection (p = .17) predicted 
depressive symptoms at month 14.
Vasomotor Symptoms and Other Potential Confounders
It should be noted that in our sample, vasomotor symptoms were not associated with 
depressive symptoms at any time point (ps > .39). Furthermore, although estradiol levels 
tended to be negatively associated with vasomotor symptoms at month 14 (Mean difference 
= −0.004, p = .09), estradiol variability was not associated with vasomotor symptoms at any 
time point (ps >.19), nor did vasomotor symptoms interact with very stressful life events to 
predict depressive symptoms (ps > .16).
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All analyses involving estradiol variability were rerun including the following potential 
confounders: age, race, BMI, progesterone variability and estradiol levels. However, all 
statistically significant results reported above remained statistically significant despite 
adjustment for these potential confounders.
Discussion
The current study found that estradiol variability predicted the development of depressive 
symptoms over a 14-month window of the menopause transition/early postmenopause in 
women who had a recent history of very stressful life events. Furthermore, the association of 
estradiol variability with depressive symptoms was preceded in time by its relationship with 
greater anger/ irritability and feelings of rejection to a psychosocial laboratory stressor, and 
stress-induced feelings of rejection at month 8 predicted depressive symptoms at month 14 
in those women with a recent history of very stressful life events. Taken together, these 
results may suggest that estradiol fluctuation in the menopause transition enhances 
emotional sensitivity to psychosocial stress, particularly sensitivity to social rejection; and in 
combination with recent very stressful life events this increased sensitivity may contribute to 
the development of depressed mood. Importantly, these effects of estradiol fluctuation on 
stress sensitivity and mood appear to be independent of estradiol levels and vasomotor 
symptoms that may accompany the menopause transition. However, it is important to stress 
that these results are preliminary and prone to type I error given the large number of 
analyses conducted. The current results will require replication.
Of note, the interaction between estradiol variability and total stressful life events was not 
statistically significant. It may be that stressful life events not considered very stressful, such 
as working long hours, do not have the same long-lasting mood impact that very stressful 
life events, such as the death of a loved one, might have. The fact that total stressful life 
events significantly predicted CES-D score at month 8 but not month 14 whereas the 
negative mood effects of very stressful life events actually increased from month 8 to month 
14 is supportive of this. Thus, perhaps only women suffering from very stressful life events 
at baseline would, fourteen months later, continue to show the emotional scars of those 
events. While speculative, these long-lasting emotional effects might then combine with 
prolonged exposure to estradiol variability to negatively impact mood. Another possibility is 
that the potency of very stressful life events to activate central neuroendocrine pathways that 
are both stress-responsive and modulated by estradiol is greater than stressful life events not 
considered very stressful. However, regardless of the underlying reason for which total 
stressful life events did not interact with estradiol variability, our findings are consistent 
with the fact that severe life stressors but not total life stressors have been found to predict 
perimenopausal depression7. Importantly, estradiol variability does not lead to significant 
mood disturbance in the absence of very stressful life events. If estradiol variability 
increases sensitivity to stress as the current study’s results suggest, it may be that within the 
context of this increased stress sensitivity, significant life stress is a necessary trigger for 
negative mood induction.
Although a number of studies have shown that stressful life events predict depressive 
symptomatology during the menopause transition6–8, this is the first report to identify a 
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potential mechanism that may contribute to the relationship between stress and depressive 
symptoms in this reproductive life phase. While our finding that estradiol variability is 
specifically correlated with rejection sensitivity, and not other emotional responses, may be 
the result of type I error, it may also suggest the possibility that estradiol fluctuation 
enhances the perception of negative social cues to impact social cognition. This is consistent 
with research in premenstrual dysphoric disorder (PMDD), a mood disorder triggered by 
ovarian hormone changes3, in which the premenstrual phase is associated with negative bias 
in the processing of facial expressions39 as well as altered corticolimbic reactivity in 
response to negative social pictures (reviewed in40). It is also consistent with evidence 
implicating rejection sensitivity as a transdiagnostic factor across psychological disorders41. 
Even in nonclinical samples, laboratory manipulations of social rejection are powerful, 
resulting in negative psychosocial effects such as increased aggression42 and acute 
depressive symptoms43. If estrogen variability indeed increases perceived social rejection, 
this disturbance may mediate links to other negative interpersonal and affective outcomes in 
the menopausal transition.
One potential mechanism by which estradiol variability may influence sensitivity to 
rejection and mood may involve the modulation of hypothalamic oxytocin production by 
estrogen receptor (ER) activation44–47. Mounting evidence suggests that central oxytocin 
acts on the limbic system to increase the salience of social cues, positive and negative, and 
enhance affective responses to those cues (reviewed in48). Therefore, as discussed by Bartz 
et al.49, oxytocin’s effect on responses to social cues depends largely on context - enhancing 
positive responses to pro-social cues and having the opposite effect within the context of 
social rejection, particularly in women50–53. However, it should be noted that these studies 
are constrained by either the use of plasma oxytocin as an imperfect indicator of central 
levels or by the use of intranasal administration of oxytocin, which has a short half-life. 
Nonetheless, we might postulate that prolonged periods of low estradiol concentrations, 
which are characteristic of the menopause transition5, could result in hypothalamic ERβ 
sensitization, thus enhancing estradiol’s effect on oxytocin release following a long period 
of low estradiol. High levels of oxytocin may then increase sensitivity to rejection within the 
context of the TSST, as is suggested by a previous study examining the effects of intranasal 
oxytocin on emotional responses to the TSST51.
An alternative, though not mutually exclusive, possibility that has been recently suggested4 
is that perimenopausal estradiol variability may, via alterations in GABAergic inhibitory 
control, contribute to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis 
response to stress and consequently contribute to the development of perimenopausal 
depression. Both proposed mechanisms are currently speculative, though future research 
investigating the relationships between changes in estradiol, oxytocin, cortisol and mood in 
the menopause transition is warranted. It is also possible that other well-known risk factors 
for perimenopausal depression, such as having a family history of depression9 may increase 
the likelihood that a life event would be perceived as very stressful within the context of 
estradiol variability. Future research should therefore investigate the potential moderating 
role of other risk factors for depression as well. Other steroid hormones such as androgens 
may also be relevant to perimenopausal depression. Although not measured in the present 
study, the investigation of androgens in the etiology of perimenopausal depression is 
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warranted given that androgens, including dehydroepiandrosterone (DHEAS) and 
testosterone, rise during the perimenopausal and early postmenopausal years54 and this rise 
has been implicated in perimenopausal depression in one previous study55.
The current study should be interpreted in light of its limitations. First, although the estradiol 
measurement schedule is substantially more frequent than that of previous studies, it is still 
imprecise in capturing the true degree of hormonal fluctuation to which a woman is exposed 
during the menopause transition. Second, it is limited by its single measurement of life 
stress. Third, unless participants scored >16 on the CES-D during interim study visits, in 
which case a psychiatric interview was administered to determine the presence or absence of 
MDD, depressive symptoms used in analyses in this study were solely assessed using a self-
report questionnaire. Fourth, due to the current study’s small sample size and therefore 
already limited statistical power, we chose not make any adjustments for multiple 
comparisons to reduce the family-wise error rate. Finally, because the data presented here 
are from a randomized controlled trial with many exclusion criteria, including baseline 
psychopathology, its participants may not be representative of the general population of 
perimenopausal women and is likely above average in both mental and physical health. We 
hypothesize that the effects of estradiol fluctuation on mood may have been even more 
pronounced had this study been more inclusive. The fact that the women in this study were 
participants in a randomized controlled trial may also have dampened the effect of estradiol 
variability on mood by creating an expectation that hormone therapy would benefit mood 
and other perimenopausal symptoms. A placebo effect may have therefore prevented 
depressive symptoms from becoming as elevated as they otherwise would have.
Despite these limitations, the current study addresses several gaps in the current literature on 
estradiol variability and perimenopausal depression development. It is the first to examine 
the relationship between estradiol variability and emotional responses to the TSST, allowing 
us to examine increased stress sensitivity as a candidate mechanism linking estradiol 
variability and perimenopausal depression symptomatology. It is also the first study to 
examine potential moderating variables in linking perimenopausal estradiol variability and 
depressive symptoms. Furthermore, by excluding depressed women at baseline, the current 
study also ensured that any clinical elevations in depressive symptoms observed had their 
onset in the menopause transition.
Conclusions
The current study’s findings suggest that perimenopausal estradiol fluctuation may increase 
women’s sensitivity to social rejection, and when this sensitivity is combined with 
psychosocial stressors such as divorce or bereavement, women are particularly vulnerable to 
the development of clinically significant depressive symptoms. Should these preliminary 
findings be confirmed in future research, they may have important clinical implications, 
suggesting that depressive symptoms might be prevented and/ or treated in at least two 
ways. First, by implicating estradiol fluctuation in the etiology of perimenopausal 
depression, the current study provides support for the use of transdermal estradiol as a 
treatment for perimenopausal depression through the stabilization of estradiol levels. To 
date, small RCTs find that transdermal estradiol is more effective than placebo at decreasing 
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depressive symptoms and treating MDD in perimenopausal women56–58 – the current study 
provides indirect evidence that estradiol stabilization may be the mechanism underlying 
these results. Second, because estradiol fluctuation was associated with both increased 
sensitivity to psychosocial stress and development of depressive symptomatology, the 
current study’s results may also suggest a role for the use of psychosocial interventions 
aimed at increasing resilience in the face of stress to prevent and/ or treat perimenopausal 
depression. For example, multiple studies suggest that mindfulness meditation training59, 60 
and mindfulness based cognitive therapy61 decrease negative emotional responses to 
psychosocial stress. These interventions are also known to prevent the onset of depression in 
at-risk populations62, 63. However, studies testing the efficacy of these interventions to 
promote mental health in the menopause transition are needed.
Importantly, if the current study’s findings are replicated, they suggest that the effect of 
estradiol variability on mood is not the same in all women. In fact, unless severe life stress 
was present, estradiol variability did not predict depressive symptoms in this sample. In 
clinical practice, an assessment of current life stress may therefore be used to identify 
women who are most vulnerable to developing perimenopausal depression and perhaps most 
likely to benefit from the prophylactic interventions. Future research should continue to 
search for moderators in the relationship between estradiol fluctuation and perimenopausal 
depression to inform and advance individualized medicine for improving quality of life for 
women in the menopause transition.
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Figure 1. 
Study design.
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Figure 2. 
Mean (+SEM) month 14 CES-D score as a function of low versus high very stressful life 
events at baseline and E2 variability (both split at the median) adjusting for baseline CES-D 
score. N = 42; *p<.05
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Figure 3. 
Mean (+SEM) month 8 post-TSST emotional ratings as a function of low versus high 
estradiol variability (based on a median split), adjusting for perceived task difficulty and 
perceived effort. N = 47; *p<.05 **p<.001
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Figure 4. 
Mean (+SEM) month 14 CES-D score as a function of very stressful life events at baseline 
and post-TSST feelings of rejection at month 8, adjusting for perceived task difficulty and 
perceived effort; N = 44 *p<.05
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Table 1
Participant characteristics
Variable Mean (SD) or %
Age 50.9 (3.0)
Household Income $80 000 – 99 999
Race
  % Caucasian 73.1%
  % African American 23.1%
  % Other 3.8%
Mean GCS Vasomotor subscale score (/6)
  Baseline 2.1 (1.7)
  Month 14 1.4 (1.5)
History of major depressive disorder (%) 30.8%
Mean CES-D score
  Baseline 5.0 (3.8)
  Month 14 6.5 (7.3)
Mean CES-D score change (Months 0 to 14) 2.0 (7.0)
% Reporting baseline very stressful life events 38.5%
% CES-D score >16
  Baseline 0%
  Month 14 7.7%
Mean estradiol change (pg/ml) (Months 0 to 14) 7.0 (80.0)
Estradiol (pg/ml)
  Baseline 127.5 (102.2)
  Month 1 97.4 (54.4)
  Month 8 97.3 (56.8)
  Month 14 127.2 (100.1)
Mean progesterone change (pgml) (Months 0 to 14) −0.8 (6.2)
Progesterone (pg/ml)
  Baseline 1.8 (3.9)
  Month 1 1.5 (4.4)
  Month 8 1.9 (5.9)
  Month 14 1.2 (4.3)
Menopausal Status at Baseline
  Early perimenopausal 29.6%
  Late perimenopausal 61.4%
  Postmenopausal 9.1%
  Estradiol < 40 pg/ml 1.9%
Menopausal Status at Month 14
  Early perimenopausal 17.8%
  Late perimenopausal 48.9%
  Postmenopausal 33.3%
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Variable Mean (SD) or %
  Estradiol <40pg/ml 7.1%
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